You are here

Home » Content

DÎYALÎZ HASTALARINDA L-CARNÎTÎNE TEDAVİSİNİN ERİTROSİT OSMOTİK FRAJÎLÎTE ÜZERİNE ETKİLERİ

THE EFFECTS OF L-CARNITINE ON ERYTHROCYTES OSMOTIC FRAGILITY IN DIALYZED PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The aim of this study was to investigate the effects of L-Camitine (LC) treatment on erythrocyte osmotic fragility (EOF) that important cause of anemia in diyalized patients. 35 patients, with mean age 46.4±14 years on meintenance dialysis (17 heamodialysis-HD, 18 continious ambulatory periyonel dialysis-CAPD) and 44 healty individiuals with mean age 45±9 years were included to study. . Patients group received LC 2 g /day for 4 months then 20-25 mg/kg 3 days a week, for following 12 months. At initial, haemoglobin (Hb),haemotocrit (Hct) and Erythrocyte (Er) inpatients were lower (P<0.000) and EOF was higher (P<0.005) than those of the controls. Hb, Hct, Er were increased in 4 months then continued in further 12 months (P<0.0005, <0.005, <0.05). EOF decreased after 16 months and after discontinued LC, it showed to return the baseline value, but still was higher (<0.005) after 4 months discontinued LC . Free Carnitine increased after 16 months (P<0.000). Our findigs suggest that improvoment in anemia with LC treatment was due to decrasing effects of its on EOF.
Bookmark/Search this post with
Abstract (Original Language): 
Çalışmamızda, 17Hemodiyaliz (HD), 18 devamlı ayaktan periton diyalizi (DAPD) tadavisindeki, yaş ortalaması 46,4±14yıl ve diyaliz süresi 37,8±30 ay olan 35 hastada L-Carnitine (LC) tedavisinin eritrosit osmotik frajilite (EOF) üzerine etkileri incelendi. Yaş ortalaması 43,8±7 yıl olan 44 sağlıklı birey kontrol olarak alındı. Hastalara 4 ay 2g/gün, izleyen 12 ay 20-25 mg/kg/haftada 3 gün, toplam 16 ay LC tedavisi (HD'de diyaliz sonu İ.V.,DAPDde P.O.) uygulandı. Başlangıçta kontrolden düşük olan (P<0.000) hemoglobin (Hb), hematokrit (Hct), eritrosit (Er) değerlerinde tedavi ile 4 ve 16 ayda artma (P<0.0005,<0.005 ve <0.05) oldu. Tedavi kesildikten 4 ay sonra Hb yüksek kaldı (P<0.005). Yirmi hastada yüksek olan EOF(%0.53) 16ayda düştü (%0.42). LC kesildikten 4 ay sonra (%0.48) başlangıçdan düşük olan yükselme (P<0.005) gözlendi. Plazma serbest Carnitine, 16 ayda belirgin yükseldi (P<0.000). Bulgularımız, LC tedavisinin diyaliz hastalarındaki anemiyi düzeltmede EOF'ni azaltıcı etkisinin önemli rol aldığını göstermektedir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_261.pdf
  • 3
152-156
  • Turkish

REFERENCES

References: 

1. Desforges JF. Anemia on uremia. Arch Intern Med 1970;126:808-811.
2. Bogin E, Massry SG, Levi J, Djaldeti M, Bristol G, Smith J. Effects of parathyroid hormone on osmotic fragility of human erythrocytes. J Clin Invest 1982;69:1071-1025.
3. Wu SG, Jeng FR, Wei SY, Su CZ, Chung TC et al. Red blood cell osmotic fragility in chronically hemodialyzed
patients. Nephron 1988;78:28-32.
4. Massry SG, Akmal M. Osmotic fragility of red blood cells,secondary hyperparathyroidism, and uremia. Nephron 1986;43:70-71.
5. Docci D. Osmotic fragility of erythrocytes and secondary hyperparathyroidism in chronic renal failure.
Nephron 1987;45:247-248.
6. Foulks CJ, Mills GM, Wright LF. Parathyroid hormone and anaemia an erythrocyte osmotic fragility study in primary and secondary hyperparathyroidism. Postgrad Med J 1989;65:136-139
7. Trovato GM, Ginardi V, Di Marco V, Dell'aira AE,
Corsi M. Long-term L-Carnitine treatment of chronic anaemia of patients with end-stage renal failure.Cur
TherRes 1982;31:1042-1049.
8. Ahmad S, Robertson HT, Golper TA, Wolfson M,
Kurtin P. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and
biochemical effects. Kidney Int 1990;38:912-918.
9. Izumo H, Izumo S, DeLuise M, Fher JS. Erythrocyte Na.K pump in uremia. Acute correction of a transport
defect by hemodialysis. J Clin Invest 1984;74:581-588
10. Labonia WD, Morelli OH, Jr Gimenez Mİ, Frenter PU. Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients. Kidney Int 1987;32:754-759.
11. Donatelli M, Terrizzi C, Zummo G, Russo M, Bucalo ML, Scarpinato A. Effects of L-Carnitine on chronic anemia and erythrocyte adenosine triphosphate concentration in hemodialyzed patients. Cur Ther Res 1987;41:620-624
12. Arduini A, Tyurin V, Tyuruna Y, Martelli EA, Molajoni F, Federici G. Acyl-traficking in membrane phospholipid fatty acid turnovenThe transfer of fatty acid from the acyl-L-carnitine pool to membrane phospholipids in intact human erythrocytes. Biochem
Biophys Res Commun 1992;187:353-358.
13. Berard E, Barrilon D, İordache A, Bayle J, Cassuto-Viguier E. Low dose L-carnitine impairs membrane fragility of erythrocytes in hemodialysis patients.
Nephron 1994;68:145.
14. Sen S, Yüksel M, Gümüştaş K et al. The effects of L-carnitine on anemia RBC survival, dyslipidemia, endothelial function in dialysis patients. Nephrol Dial Transplant 1988;31(6):A165 (Abstarcts).
15. Yüksel M, Şen S, Işıklar H. Is L-carnitine a survival faktör for red blood cells in dialysis patients. Nephrol Dial Transplant 1999;14(9):A6 (Abstract).
16.
Hoppe
l C. The physiologycal role of carnitine. İn L-carnitine and it's role in medicine from fuction to therapy. Ferrari R, Dimarro S, Sherwood G. Academic pres-Ltd. London 1992;pp 5-21
17. Guerniero GF, Toigo G, Crapesi L et al. Carnitine metabolysim in choronic renal failure: Acute effects of carnitine addition todialysate during acetate
hemodialysis. Contr Nephrol 1988;65:1-23.
18. Wood
JM
, Bush B, Pitts BJR, Schwartz G. Inhibition of bovine heart Na-K-ATPase by palmtyl carnitine and palmtyl-CoA. Biochem Biophys Res Commun 1977;74:677-684
19. Matsumura M, Hatakeyama S, Koni I, Mabuchi H, Muromuto H. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis
patients. Nephron 1996;72:574-578.
20. Maeda K, Shinzato T, Kobayakawa H. Effects of L-carnitine administration on short-chain fatty acid (Acetic Acid) and long-chain fatty acid metabolism during hemodialysis. Nephron 1989;51:355-361.
21. Şen S, Çermik TF, Sankaya A, Gümüştaş K, Belce A, Yüksel M. Short and long term effect of L-carnitine on skeletal muscle metabolism and nutritional status in dialyzed patiets. Nephrol Dial Transplant
1999;14(9):A8 (Abstracts).
22. Böhles HJ, Akcetin S. Ketogenic effects of low and high
levels of carnitine during total parenteral nutrition in the
rat. Am J Clin Nutr 1987;46:47-51.

Thank you for copying data from http://www.arastirmax.com